

Cleansing Notice

Life sciences company eSense-Lab Ltd (“eSense” or the “Company”), (ASX: ESE), hereby notifies the ASX that the Company on 21 November 2017 issued 6,478,000 CHESS Depository Interests (CDI’s) (representing 6,478,000 underlying ordinary shares) as part of a Placement to raise \$1,619,500 before costs. The Company also issued 2,500,000 CDI’s (representing 2,500,000 underlying ordinary shares) in respect of a strategic investment of \$500,000. The issue of a total of 8,978,000 CDI’s fall within the Company’s existing placement capacity under ASX Listing Rule 7.1. An Appendix 3B in respect of the Placement has been lodged with the ASX and provides further detail on the allotment of securities.

The Australian *Corporations Act 2001* (Cth) (**Corporations Act**) restricts the offer for sale of securities without a disclosure document unless the relevant sale satisfies an exemption set out in section 708 or section 708A of the Corporations Act. ASIC Class Order [CO 14/827] (**Class Order**) provides relief so that an offer of CDIs over underlying foreign securities is regulated as an offer of securities under the Corporations Act. The Company seeks to rely on an exemption in section 708A of the Corporations Act (as modified by the Class Order) with respect to any sale of the CDIs.

As required by section 708A(5)(e) of the Corporations Act as modified by the Class Order, the Company gives notice that:

1. The CDI’s were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. The Company, as at the date of this notice, has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 of the Corporations Act.
3. As at the date of this notice, there is no information, for the purposes of section 708A(7) and 708A(8):
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the CDI’s.

Ends



About eSense-Lab

eSense-Lab Limited (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost.

To learn more about eSense – Lab, visit www.esense-lab.com

All enquires please contact:

Corporate Advisors

Otsana Capital

108 Outram Street

West Perth WA 6005

Telephone: +61 8 9486 7244

www.otsana.com